

## WEST



Generate Collection

Print

L16: Entry 8 of 9

File: DWPI

Aug 25, 1999

DERWENT-ACC-NO: 1992-070067  
DERWENT-WEEK: 199940  
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Oral compsn. acting as anti-vasodepressor and ACE inhibitor activity - contains carnosine, anserine and valenine or their derivs.

## PATENT-ASSIGNEE:

## ASSIGNEE

MARUDAI SHOKUHIN KOGYO KK

NIPPON SHINYAKU CO LTD KK

## CODE

MARUN

NNSH

PRIORITY-DATA: 1990JP-0118125 (May 7, 1990)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2939301 B2	August 25, 1999		005	A23L001/305
JP 04016166 A	January 21, 1992		005	

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP 2939301B2	May 7, 1990	1990JP-0118125	
JP 2939301B2		JP 4016166	Previous Publ.
JP04016166A	May 7, 1990	1990JP-0118125	

INT-CL (IPC): A21D 13/00; A23C 9/152; A23G 3/30; A23L 1/10; A23L 1/16; A23L 1/30; A23L 1/305; A23L 1/317; A23L 1/325; A61K 31/00; A61K 37/64; A61K 38/55

ABSTRACTED-PUB-NO: JP04016166A

## BASIC-ABSTRACT:

A compsn. of oral ingesta for vasodepression contains carnosine, anserine, valenine or their acid additive salts as active components.

Carnosine, anserine, valenine, are extracted and purified from natural prods., e.g. broth in prepn. of dried bonito or dried small sardines, tinned food of tuna or from meat of wasted chicken. Chemically synthesised cpds. may also be used. As drugs, the cpds. may be used singly or combinatory, and administered orally by common dosage forms. As oral ingesta, the cpds. are combined with casein, whey, soybean protein, egg albumin, etc. or their hydrolysates. They are also combined in various foods, drinks, etc.

USE/ADVANTAGE - The compsn. (food or drug) has an antivasopressing effect. Components have ACE inhibiting effect. The toxicity is low and safety is high.

In an example, carnosine (20 parts), lactose (61.5 parts), sucrose (0.05 part) and CMC (7.5 parts) were suspended in hydroxypropyl-methylcell ulose (5 parts) contg. 70% ethanol aq. soln. (25 parts). After kneading it was vacuum dried. To this, Mg-stearate (1 part) and Na starch glycolate (5 parts) were added, and tabletted by a common method.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: ORAL COMPOSITION ACT ANTI VASODEPRESSIVE ACE INHIBIT ACTIVE CONTAIN

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>			
<u>L17</u>	l8 and ( drink or nutrition or composition)	126	<u>L17</u>
<u>L16</u>	valenine	9	<u>L16</u>
<u>L15</u>	valeninr	0	<u>L15</u>
<u>L14</u>	valeninr	0	<u>L14</u>
<u>L13</u>	L12 same imidazole	99	<u>L13</u>
<u>L12</u>	valine	20189	<u>L12</u>
<u>L11</u>	valine and valenine	0	<u>L11</u>
<u>L10</u>	valine same valenine	0	<u>L10</u>
<u>L9</u>	L8 and ribose	16	<u>L9</u>
<u>L8</u>	l1 same (taurine or creatine or (vitamin\$))	144	<u>L8</u>
<u>L7</u>	l4 and (stress or fatigue or energ\$)	60	<u>L7</u>
<u>L6</u>	l4 and (anti\$)	128	<u>L6</u>
<u>L5</u>	L4 and ribose	22	<u>L5</u>
<u>L4</u>	l1 and (taurine or creatine or (vitamin\$))	237	<u>L4</u>
<u>L3</u>	l2 and (d adj1 ribose)	7	<u>L3</u>
<u>L2</u>	l1 same (D adj1 ribose)	7	<u>L2</u>
<u>L1</u>	(anserine or carnosine or valenine)	497	<u>L1</u>

END OF SEARCH HISTORY

## WEST

## End of Result Set



Generate Collection

Print

L17: Entry 126 of 126

File: DWPI

Jun 14, 1990

DERWENT-ACC-NO: 1990-209605

DERWENT-WEEK: 199027

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Retardation of collagen crosslinking in skin - by treating with compsn.  
including anti-oxidase cpd., e.g. carnosine, anserine, 3-methyl -L-histidine, etc.

INVENTOR: GRIGG, G W; HANNAN, G N

## PATENT-ASSIGNEE:

## ASSIGNEE

COMMONWEALTH SCI &amp; IND RES ORG

PEPTIDE TECHNOLOGY LTD RES ORG

PEPTIDE TECH LTDGY LTD RES ORG

PEPTIDE TECHN LTDY LTD RES ORG

## CODE

CSIR

PEPTN

PEPTN

PEPTN

PRIORITY-DATA: 1988AU-0000675 (September 28, 1988)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9006102 A	June 14, 1990		000	
AU 638681 B	July 8, 1993		000	A61K007/40
AU 8943320 A	June 26, 1990		000	
EP 436611 A	July 17, 1991		000	
EP 436611 A4	March 11, 1992		000	
JP 04502611 W	May 14, 1992		011	A61K037/02

DESIGNATED-STATES: AU JP US AT BE CH DE FR GB IT LU NL SE DE FR GB IT

CITED-DOCUMENTS: DE 3424781; GB 2143732 ; FR 2609393

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
AU 638681B	September 28, 1989	1989AU-0043320	
AU 638681B		AU 8943320	
AU 638681B		WO 9006102	Based on
EP 436611A	September 28, 1989	1989EP-0910999	
EP 436611A4		1989EP-0910999	
JP04502611W	September 28, 1989	1989JP-0510274	
JP04502611W	September 28, 1989	1989WO-AU00422	
JP04502611W		WO 9006102	Based on

INT-CL (IPC): A61K 7/00; A61K 7/40; A61K 7/48; A61K 37/02

ABSTRACTED-PUB-NO: WO 9006102A

## BASIC-ABSTRACT:

A method for reducing or preventing collagen crosslinking in skin and/or damage to skin cell DNA is claimed comprising treating the skin with a compsn. comprising an excipient and an active cpd. (I) selected from carnosine, homocarnosine, anserine,

3-methyl-L-histidine, L-alanyl-L-tyrosine, acyl homocarnosine, acetyl carnosine, iodo carnosine, di-iodo carnosine, anserine nitrate, carbenoxylone carnosine and analogues. The compsn. may also contain a cpd. (II) selected from bilirubin, carotenoids, mannitol, reduced glutathione, selenium, uric acid, vitamin A, vitamin B and vitamin C.

USE/ADVANTAGE - (I) are antioxidant dipeptides which can decrease or prevent collagen crosslinking either during ageing and/or following exposure to UV radiation or sunlight. The method can also prevent DNA damage as a result of UV radiation and can prevent skin cancer. (II) are non-peptide cpds. which can also inhibit or prevent crosslinking of collagen.

CHOSEN-DRAWING: Dwg.0/14

TITLE-TERMS: RETARD COLLAGEN CROSSLINK SKIN TREAT COMPOSITION ANTI OXIDASE COMPOUND CARNOSINE ANSERINE METHYL HISTIDINE

DERWENT-CLASS: B05 D21 E19

CPI-CODES: B03-L; B04-A06; B05-B02C; B07-D02; B07-D09; B10-A07; B10-B02D; B10-B02E; B10-E04C; B12-A07; B12-M06; D08-B09A; D09-E; E05-K; E06-A01; E10-A07;

CHEMICAL-CODES:

#### Chemical Indexing M2 \*01\*

##### Fragmentation Code

F013 F014 F521 H100 H181 H182 H201 J0 J012 J013  
J1 J171 J271 J3 J371 M210 M211 M212 M213 M214  
M215 M216 M220 M221 M222 M231 M232 M233 M262 M273  
M280 M281 M312 M313 M321 M322 M332 M342 M343 M349  
M371 M381 M391 M413 M431 M510 M521 M530 M540 M640  
M782 M903 M904 P943 Q254 Q262

##### Specific Compounds

08807M 11742M 19176M

##### Markush Compounds

199027-35401-M

##### Registry Numbers

1327U 0502U

#### Chemical Indexing M2 \*02\*

##### Fragmentation Code

F013 F014 F521 G013 G100 H1 H100 H181 H182 H201  
H401 H441 J0 J011 J012 J1 J171 J371 M210 M211  
M273 M280 M281 M311 M312 M321 M331 M340 M342 M343  
M349 M371 M381 M391 M413 M431 M510 M521 M530 M531  
M540 M782 M903 M904 P943 Q254 Q262

##### Specific Compounds

11679M 19930M

##### Registry Numbers

1327U 0502U

#### Chemical Indexing M2 \*03\*

##### Fragmentation Code

F012 F013 F014 F015 F019 F421 F422 F499 H7 H715  
H720 H723 J0 J012 J1 J172 J5 J522 L9 L941  
L999 M1 M126 M129 M132 M139 M210 M211 M212 M240  
M283 M311 M312 M322 M323 M332 M342 M343 M372 M392  
M413 M431 M510 M523 M530 M540 M782 M903 M904 M910  
P943 Q254

CARNOSINE ANSERINE DERIVATIVE

DERWENT-CLASS: B05 D13

CPI-CODES: B07-D09; B12-F05A; B12-F06; D03-H01T;

CHEMICAL-CODES:

Chemical Indexing M2 \*01\*

Fragmentation Code

F011 F015 F521 H1 H100 H181 H182 H201 J0 J012  
J1 J171 J3 J371 M210 M211 M273 M280 M281 M312  
M322 M332 M342 M343 M349 M371 M381 M391 M413 M510  
M521 M530 M540 M640 M650 M781 M800 M903 M904 P527  
P616 V815

Specific Compounds

08807U 11742U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1992-032303

**Set Name Query**

side by side

**Hit Count Set Name**

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

<u>L27</u>	(carnosine or balenine or \$methylhistidine) and ribose	63	<u>L27</u>
<u>L26</u>	(D adj1 ribose) and ( fatigue)	34	<u>L26</u>
<u>L25</u>	(D adj1 ribose) and (muscl\$ near fatigue)	7	<u>L25</u>
<u>L24</u>	(D adj1 ribose) and (muscle or fatigue or nutritional or nutrition or rehydration or supplement)	391	<u>L24</u>
<u>L23</u>	ribose and (muscle or fatigue or nutritional or nutrition or rehydration or supplement)	2561	<u>L23</u>
<u>L22</u>	anserine and (muscle or fatigue or nutritional or nutrition or rehydration or supplement)	54	<u>L22</u>
<u>L21</u>	anserine and (muscle or fatigue or nutritional or nutrition or rehydration or supplment)	50	<u>L21</u>
<u>L20</u>	L19 and ribose	79	<u>L20</u>
<u>L19</u>	(nutritional near supplements)	3068	<u>L19</u>
<u>L18</u>	carnosine and (ribose or \$ribose)	37	<u>L18</u>
<u>L17</u>	L16 same anserine	2	<u>L17</u>
<u>L16</u>	histidine near imidazole	223	<u>L16</u>
<u>L15</u>	histidine same imidazole	2139	<u>L15</u>
<u>L14</u>	(carnosine or anserine) and (ribose)	33	<u>L14</u>
<u>L13</u>	anserine	300	<u>L13</u>
<u>L12</u>	L10 and ( ribose)	20	<u>L12</u>
<u>L11</u>	L10 and (d adj1 ribose)	2	<u>L11</u>
<u>L10</u>	l8 and (rehydration or supplement or nutritional or muscular or fatigue)	882	<u>L10</u>
<u>L9</u>	L8 and (ribose or \$ribose)	64	<u>L9</u>
<u>L8</u>	(tuna or cod or salmon or fish or chicken or poultry or meat) near (peptide or protein)	3036	<u>L8</u>
<u>L7</u>	(tuna or cod or salmon or fish or chicken or poultry or meat) same peptide	3661	<u>L7</u>
<u>L6</u>	L5 and (rehydration or supplement or nutritional or muscular or fatigue)	177	<u>L6</u>
<u>L5</u>	l2 and (\$ribose or ribose)	580	<u>L5</u>
<u>L4</u>	L3 and (\$ribose or ribose)	11	<u>L4</u>
<u>L3</u>	L2 and (nutritional near supplements)	106	<u>L3</u>
<u>L2</u>	(tuna or cod or salmon or fish or chicken or poultry or meat) same extract	10884	<u>L2</u>
<u>L1</u>	(tuna or cod or salmon or fish or chicken or poultry) same extract	5421	<u>L1</u>

END OF SEARCH HISTORY

reported